Michael E. Williams

5.9k total citations · 2 hit papers
43 papers, 4.5k citations indexed

About

Michael E. Williams is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Michael E. Williams has authored 43 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pathology and Forensic Medicine, 18 papers in Genetics and 16 papers in Oncology. Recurrent topics in Michael E. Williams's work include Lymphoma Diagnosis and Treatment (29 papers), Chronic Lymphocytic Leukemia Research (18 papers) and CAR-T cell therapy research (6 papers). Michael E. Williams is often cited by papers focused on Lymphoma Diagnosis and Treatment (29 papers), Chronic Lymphocytic Leukemia Research (18 papers) and CAR-T cell therapy research (6 papers). Michael E. Williams collaborates with scholars based in United States, Austria and Türkiye. Michael E. Williams's co-authors include Ronald Levy, Brian K. Link, A.J. Grillo-López, Christine A. White, Vinay Jain, Diying Shen, Peter McLaughlin, Anthony D. Ho, B.K. Dallaire and Isabelle Bence‐Bruckler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Michael E. Williams

43 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1998 2.2k citations Peter McLaughlin, A.J. Grillo-López et al. Journal of Clinical Oncology profile →
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

2009 673 citations S. Vincent Rajkumar, Susanna Jacobus et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael E. Williams United States	16	2.5k	2.2k	1.8k	965	947	43	4.5k
Nicolas Ketterer Switzerland	23	2.8k 1.1×	2.5k 1.2×	1.4k 0.8×	1.1k 1.1×	682 0.7×	69	4.5k
M. S. Czuczman United States	24	3.7k 1.4×	2.5k 1.1×	2.3k 1.3×	560 0.6×	717 0.8×	62	5.6k
B.K. Dallaire United States	16	2.7k 1.1×	2.0k 0.9×	1.7k 1.0×	419 0.4×	817 0.9×	19	5.0k
Isabelle Bence‐Bruckler Canada	18	2.0k 0.8×	1.5k 0.7×	1.4k 0.8×	459 0.5×	328 0.3×	62	3.5k
Karim Belhadj France	25	2.3k 0.9×	1.6k 0.7×	779 0.4×	561 0.6×	696 0.7×	101	3.6k
Yasuhiro Oki United States	40	3.1k 1.2×	2.3k 1.1×	1.7k 1.0×	1.3k 1.3×	2.2k 2.3×	207	6.3k
Jeff P. Sharman United States	33	4.0k 1.6×	1.9k 0.9×	3.9k 2.2×	1.2k 1.3×	1.0k 1.1×	245	6.1k
Nathan Fowler United States	34	3.6k 1.4×	2.9k 1.3×	2.5k 1.4×	607 0.6×	1.2k 1.2×	267	5.8k
F Reyes France	30	3.4k 1.4×	2.3k 1.1×	1.5k 0.9×	789 0.8×	424 0.4×	64	4.9k
A. Z. S. Rohatiner United Kingdom	43	4.2k 1.6×	3.1k 1.4×	2.1k 1.2×	1.3k 1.4×	854 0.9×	117	6.8k

Countries citing papers authored by Michael E. Williams

Since Specialization

Citations

This map shows the geographic impact of Michael E. Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Williams more than expected).

Fields of papers citing papers by Michael E. Williams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Williams. The network helps show where Michael E. Williams may publish in the future.

Co-authorship network of co-authors of Michael E. Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Williams. A scholar is included among the top collaborators of Michael E. Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Williams. Michael E. Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Williams, Michael E.. (2016). Revised WHO Classification of Hematologic Malignancies. Journal watch. 2016. 1 indexed citations

Kahl, Brad S., Fangxin Hong, Michael E. Williams, et al.. (2014). Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402. Journal of Clinical Oncology. 32(28). 3096–3102. 138 indexed citations

Cheah, Chan Y., Anupkumar George, Eva Giné, et al.. (2013). Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Annals of Oncology. 24(8). 2119–2123. 83 indexed citations

Williams, Michael E., et al.. (2013). Current and Emerging Therapies in Mantle Cell Lymphoma. Current Treatment Options in Oncology. 14(2). 198–211. 14 indexed citations

Williams, Michael E., Steven H. Bernstein, Pedro Jares, et al.. (2013). Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop. Leukemia & lymphoma. 54(9). 1882–1890. 6 indexed citations

Goy, André, Rajni Sinha, Michael E. Williams, et al.. (2013). Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study. Journal of Clinical Oncology. 31(29). 3688–3695. 264 indexed citations

Williams, Michael E.. (2012). Gemtuzumab Ozogamicin for Acute Myeloid Leukemia. Journal watch. 2012. 2 indexed citations

Reagan, Patrick M., Tri Minh Le, Michael E. Williams, & Nolan A. Wages. (2012). Fluoroquinolone Prophylaxis Following Induction Chemotherapy in Patients with Acute Leukemia: Patterns of Infection. Blood. 120(21). 2077–2077. 1 indexed citations

Jacobus, Susanna, Shaji Kumar, Hajime Uno, et al.. (2011). Impact of high‐risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. British Journal of Haematology. 155(3). 340–348. 23 indexed citations

10.

Williams, Michael E.. (2009). Rituximab and Progressive Multifocal Leukoencephalopathy. Journal watch. 2009. 2 indexed citations

11.

Rajkumar, S. Vincent, Susanna Jacobus, Natalie S. Callander, et al.. (2009). Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology. 11(1). 29–37. 673 indexed citations breakdown →

12.

Robinson, Katherine, Michael E. Williams, Richard H. van der Jagt, et al.. (2008). Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 26(27). 4473–4479. 250 indexed citations

13.

Jagt, Richard H. van der, Philip Cohen, Bruce D. Cheson, et al.. (2006). Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin’s Lymphoma.. Blood. 108(11). 2710–2710. 6 indexed citations

14.

Densmore, John & Michael E. Williams. (2003). Mantle cell lymphoma. Current Treatment Options in Oncology. 4(4). 281–287. 6 indexed citations

15.

Ingram, Richard M., et al.. (2002). Testicular Lymphoma: A Literature Review and Report of a Case with a Zoster-Like Cutaneous Recurrence. Clinical Lymphoma. 2(4). 238–241. 2 indexed citations

16.

McLaughlin, Peter, A.J. Grillo-López, Brian K. Link, et al.. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.. Journal of Clinical Oncology. 16(8). 2825–2833. 2153 indexed citations breakdown →

17.

Kantor, William M. & Michael E. Williams. (1996). New Flag-Transitive Affine Planes of Even Order. Journal of Combinatorial Theory Series A. 74(1). 1–13. 13 indexed citations

18.

Williams, Michael E., et al.. (1995). Semiconductor industrial hygiene handbook : monitoring, ventilation, equipment, and ergonomics. 5 indexed citations

19.

Meredith, Scott D., P. A. Levine, James A. Burns, et al.. (1995). Chromosome 11q13 Amplification in Head and Neck Squamous Cell Carcinoma: Association With Poor Prognosis. Archives of Otolaryngology - Head and Neck Surgery. 121(7). 790–794. 124 indexed citations

20.

Williams, Michael E.. (1994). Catastrophic versus noncatastrophic extinction of the dinosaurs: testing, falsifiability, and the burden of proof. Journal of Paleontology. 68(2). 183–190. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact